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attendees to make the vaccine part of their countries’ 
standard immunization program. We must continue to 
share this information with other countries so that we take 
advantage of every opportunity to prevent deaths from Hib 
disease among children.”  
   -Dr. Rana Hajjeh, CDC scientist and  
                                                                          Director of the Hib Initiative
Haemophilus influenzae type b (Hib) is a bacterial 
disease that each year causes pneumonia and meningitis 
in young children, resulting in three million illnesses and 
WELCOME to the second quarter global health 
E-Brief, designed to inform readers about key global 
health activities at the CDC (Centers for Disease 
Control and Prevention). Our second issue for 2008 
spotlights the use of surveillance and research data 
to inform policies, and the life-saving power of these 
policy decisions -  when implemented.  For example, 
after a two-day meeting, 14 African countries made 
policy decisions that will impact over four million 
children -- with implementation, they will be eligible 
to receive a life-saving vaccine to prevent them from 
pneumonia and meningitis; and, CDC and the World 
Health Organization have developed a groundbreaking 
surveillance method to help prove the effectiveness of 
antiretroviroal treatment (ART) expansion programs.
Data Convince African Countries to Provide 
Life-Saving Vaccines that Prevent Meningitis 
“Last June I attended a meeting at the World Health 
Organization (WHO) headquarters for the African Region in 
Brazzaville, Congo. The journey there from the United States 
involved two 10-hour flights, an overnight stay in a run-down 
hotel in Kinshasa, the capital of the Democratic Republic of 
Congo, and an early morning boat ride the next day across 
the Congo river into Brazzaville. Representatives from 21 
African countries made the same river crossing to discuss 
introduction of new vaccines in their countries. As director 
of the Hib Initiative, an international consortium funded by 
the GAVI Alliance (formerly the Global Alliance for Vaccines 
and Immunisation), including CDC, WHO, the London School 
of Hygiene and Tropical Medicine, and the Johns Hopkins 
Bloomberg School of Public Health, my goal was to increase 
awareness about Hib vaccine-- a life saving childhood 
vaccine.  Few of the representatives attending the Brazzaville 
meeting had considered the need for Hib vaccine, mainly 
because they were not aware of Hib as an important cause 
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400,000 deaths.  Bacterial meningitis alone kills more 
than 65,000 young children in the developing world 
each year.  The United States has been able to virtually 
eliminate pediatric bacterial meningitis through several 
interventions including the introduction of Hib vaccines.  
A safe and effective vaccine has existed since the early 
1990s.  However, Hib vaccines are still not used in many 
developing countries despite compelling evidence of the 
tremendous disease burden from Hib around the world, 
the tremendous potential to prevent this large disease 
burden, and WHO recommendations for every country to 
add Hib vaccine to their infant immunization programs.
The reluctance of many countries to use the Hib 
vaccine is because of lack of local data on the disease 
burden. Many of these countries have no or poor 
surveillance systems for bacterial diseases. The Hib 
Initiative and CDC are helping to fill this gap in Africa 
by strengthening systems such as the WHO-supported 
Pediatric Bacterial Meningitis Surveillance System (PBMS), 
run by the World Health Organization in Africa.  PBMS is a 
22-country surveillance network that helps to accurately 
diagnose and record data on meningitis infections in 
young children who are seen at regional and national 
reference hospitals.  The individual parts of the network 
then share the surveillance data with decision-makers at 
the country level. 
At the meeting attended by Dr. Hajjeh, country, regional 
and global level surveillance data gathered with the PBMS 
network for bacterial meningitis and pneumonia were 
presented. Convinced by the data, every country who had 
not yet introduced the Hib vaccine committed to adding 
it to their country’s national immunization program. With 
the implementation of this new policy decision, more than 
four million children are now eligible for this life-saving 
vaccine.
CDC Research Leads to New Tools to Fight 
Malaria and Anemia in Pregnant Women 
Dr. Meghna Desai, one of CDC’s lead malaria researchers, 
was treating a Kenyan child for anemia, when she noticed 
the child’s mother was very pale and looked pregnant.  Dr. 
Desai knew if the mother was pregnant and had anemia 
(a common consequence of malaria), her pregnancy could 
be threatened.  The experience sparked her interest in 
studying the effects of malaria during pregnancy, in the 
hopes of making health system changes that would help 
mothers like this one – and ultimately ensure that their 
babies were born healthy.
Each year approximately 50 million women living in 
regions with high rates of malaria – 25 million of whom are 
in Africa – become pregnant and are at risk from malaria 
and its particularly harmful effects during pregnancy.  
During pregnancy, women lose some of the immunity to 
malaria they have acquired from living in high-risk areas. 
If they acquire malaria and develop anemia, their children 
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Bacterial Meningitis Surveillance in Uganda
Despite an ongoing 20-year conflict between rebel and 
government forces, CDC has helped implement a pediatric 
bacterial meningitis surveillance system in Uganda’s Gulu 
District.
 Charles Anywar, who grew up in this region, holds 
two jobs, one as a nurse in one of the busiest hospitals 
in northern Uganda, and the other as the PBMS data 
manager.  He works with Dr. Robert Iriso, pediatrician and 
PBMS coordinator at the hospital, to record information 
on new cases of suspected meningitis, track patients’ lab 
results, and follow up with patients and their physicians 
to determine survival rates. After collecting and entering 
the data into the PBMS database, Charles forwards 
the information to Dr. Annet Kisakye, the National 
Surveillance Officer for the Ugandan Expanded Program on 
Immunizations with the Ministry of Health, to be combined 
with data from the other hospitals.  
Uganda introduced Hib vaccine in June 2002 with funding provided by the GAVI Alliance (formerly the Global Alliance 
for Vaccines and Immunization).  PBMS data demonstrated that the Hib vaccine is highly protective and each year prevents 
almost 30,000 cases of severe Hib disease (both meningitis and pneumonia) and more than 5,000 deaths among children 
younger than five.  These data convinced the government of Uganda to commit national resources to use the Hib vaccine.
                 Charles Anywar pilot tests the new data management module for pediatric bacteria 
meningitis surveillance.
are more likely to be born small – and are more likely to 
be sick or die.  In Africa, low birth weight associated with 
malaria in pregnancy is estimated to contribute to 100,000 
infant deaths each year.
CDC malaria research plays a critical role in ensuring 
that the tools we have to combat malaria in all those 
affected by the disease can be implemented with greatest 
impact both by researching the most effective way to 
implement an intervention, and by monitoring and 
evaluating its impact.  Findings from studies conducted 
by CDC experts like Dr. Desai are the foundation for the 
way malaria in pregnant women is treated and prevented 
today and are reflected in the World Health Organization’s 
guidelines and recommendations 
for preventing and controlling 
malaria in pregnant women, 
especially in countries in sub-
Saharan Africa with high malaria 
transmission.  
Key CDC research findings 
that are preventing illness and 
saving lives are these:
•  intermittent preventive 
treatment of malaria during 
pregnancy (IPTp)—delivery 
of the right dose of effective 
antimalarial drugs as part of 
routine pre-natal care—reduced 
the risk that malaria-infected pregnant 
women would have babies with low 
birth weight and the associated high 
risks for infant death; 
•  insecticide-treated nets (ITNs) help reduce malaria 
infections and associated ill effects in pregnancy. When 
pregnant women in a study area in Kenya slept under 
ITNs, severe malarial anemia was reduced by 47% and the 
delivery of low-birth-weight infants decreased by 28%; and
•  To benefit from treatment, pregnant women who 
are HIV-positive need more doses of IPTp with the drug 
sulfadoxine-pyrimethamine (SP) or, in some cases, a 
different drug. 
CDC’s research on the usefulness of insecticide-treated 
nets and IPTp strongly influenced the strategies being 
implemented in the President’s Malaria Initiative (PMI), a 
$1.2 billion 5-year plan to reduce deaths due to malaria 
by 50 percent in 15 African countries). PMI provides IPTp, 
to pregnant women and their babies. To date, PMI has 
procured SP for IPTp for more than 1.3 million women. 
Additionally more than 5,000 health care workers have 
been trained to administer IPTp.  In addition to IPTp, 
African countries are adopting policies on the use of 
insecticide-treated bed nets and the effective treatment of 
malaria illness with antimalarial drugs to mitigate malaria’s 
ill effects in pregnant women.  
CDC, with Dr. Desai as principal investigator, is currently 
helping to plan a study in Kenya on another drug, 
mefloquine, for use in IPTp among HIV-infected pregnant 
women. The study is important for two reasons: 1) SP 
cannot be given to women who are taking cotrimoxazole, 
the drug HIV-positive pregnant women receive to prevent 
complications from their HIV; and 2) the rates of HIV and 
malaria in many sub-Saharan African countries are very 
high and the two infections overlap considerably. This 
project and other CDC research will provide additional 
information about how to prevent malaria in HIV-positive 
pregnant women. 
Innovative Threshold Survey Helps 
Preserve ART’s Life-saving Effects
Right now, over 33.2 million people are living with HIV/
AIDS – an epidemic that has long 
been one of global proportions.  
Ninety-five percent of people 
living with HIV/AIDS reside in 
developing countries. Fortunately, 
these countries are benefiting 
from significant expansion of 
antiretroviral treatment (ART), 
the main treatment for HIV/AIDS.  
While not a cure, it can prevent 
progression and symptoms of the 
disease in an individual for many 
years.
ART is dramatically improving 
the health and extending the lives 
of people who have HIV/AIDS – further 
contributing to the economic and 
social well-being of resource-poor countries. However, 
ART can lead to HIV ART drug resistance (HIVDR) if 
delivery programs are poorly designed and not enough 
drugs are available. The Centers for Disease Control and 
Prevention (CDC), as part of the President’s Emergency 
Plan for AIDS Relief (PEPFAR), is leading efforts to provide 
HIVDR surveillance in resource-limited settings, thereby 
preserving ART’s life-saving effects.  These critical 
surveillance data help guide public health policies to 
reduce occurrences of HIVDR and inform the selection 
of future drug regimens that will be effective for specific 
populations, without draining resources from other 
activities, such as higher-priority treatment, prevention 
and laboratory expansion.     
In partnership with the World Health Organization 
(WHO), CDC has developed a groundbreaking threshold 
survey that provides Ministries of Health with a relatively 
simple, rapid, and inexpensive method to estimate levels 
of HIVDR in areas where ART is being delivered.  The 
method builds on well-established surveillance systems 
and uses blood specimens that are already being gathered 
as part of a country’s routine antenatal clinic (ANC) 
surveillance. 
The scientists test a few dozen randomly selected 
specimens from eligible HIV-infected persons for viral 
genetic mutations that reduce the virus’ susceptibility to 
ART. “Then we basically provided a cheat sheet,” explains 
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Keith Sabin, a CDC expert in global HIV/AIDS surveillance, 
“requiring only check marks to simply and easily classify 
levels of resistance into one of three categories: low, 
medium, or high.”  
The “cheat sheet” is simple, but provides vital 
information to guide programs.  Those localities testing 
“low” should repeat the survey in two years; those areas 
testing “high” should expand the number of HIVDR testing 
sites, analyze program monitoring data, strengthen 
program implementation, and consider changes in 
standard ART regimens.  
The method has multiple advantages:
• the process for specimen collection already exists, 
minimizing implementation costs;
• only a small number of specimens are required;
•the results determine whether or not regimens are 
appropriate; and
• the results provide critical information on prevention 
failures.
“[This method] helps countries use their resources 
wisely, only spending additional resources on more 
intensive program monitoring if it’s needed. Then they can 
focus the funding on treating people, training workforce, 
ensuring adequate drug supply, and other essential 
program activities,” Sabin explains.
To date, CDC has helped nine countries conduct the 
threshold surveys (Tanzania, Vietnam, Malawi, Kenya, 
Ethiopia, China, Thailand, Botswana and Namibia).  
Five new countries are scheduled to conduct HIVDR 
surveillance within the year.  So far, no significant drug 
resistance has been found.  According to Sabin, “this 
simple and efficient method is showing the world that our 
remarkable ART expansion programs are working – and it 
is allowing us to ensure that they keep working.”
The Plague – Fighting Pestilence 
with Persistence
Does the plague still exist? While it is an ancient disease, 
it is certainly not gone. The plague still persists with 
approximately 1,000 to 3,000 cases worldwide each year, 
including five to 15 cases each year in the western United 
States, according to the World Health Organization.  There 
is no vaccine for this persistent disease. However, today’s 
antibiotics can treat the disease and prevent death, which 
occurs in 50% to 90% of untreated victims.
Yersinia pestis – the plague bacteria – causes swollen, 
tender lymph glands called buboes in bubonic plague, 
and fever, weakness, and pneumonia in pneumonic 
plague.  People get the bubonic plague from flea bites. 
Fleas become infected when they feed on rodents with 
the bacteria.  People are infected with pneumonic plague 
through airborne transmission, that is, by inhaling Yersinia 
pestis particles.
Most Americans today don’t worry about the 
plague, but health care and emergency preparedness 
professionals do. They worry because aerosolized Yersinia 
pestis could be used in a bioterrorist aerosol attack 
spreading the pneumonic form 
of plague.  Once people have 
the disease, the bacteria can 
spread to others who have close 
contact with them.  Because 
people don’t get sick right after 
exposure to the bacteria, they 
could travel over long distances 
and potentially infect many 
others. Controlling the disease 
at this later stage is much more 
challenging.  For all of these 
reasons, public health and 
preparedness experts recognize 
the need for continued plague 
research and preparedness, and 
control activities. The more we 
understand about plague and 
how it spreads, the greater our 
ability to control it —whether 
it strikes naturally or is released 
intentionally.  
CDC is conducting research in Uganda where 
approximately 2,000 cases of plague have been reported 
since 1999.  Efforts by the Ministry of Health to control 
the disease have had limited success because laboratory 
capacity, case follow-up, and data on the animal carriers 
of plague are essentially non-existent. Without these 
resources and information, public health professionals 
have been unable to develop policies and interventions to 
control plague and reduce associated illness and death. 
To help build regional capacity, CDC established a 
field laboratory in the Arua province of northwestern 
Uganda (near the border with Democratic Republic of the 
Congo). Staffed by CDC and local experts in laboratory, 
epidemiology, and clinical medicine, the program is 
helping to understand risk factors for plague, evaluate 
interventions targeting rodents, develop methods for 
improved diagnostics, and understand obstacles to 
treatment.  Already the laboratory has identified key ways 
in which plague is transmitted, confirmed a human plague 
case for the first time locally, and evaluated an intervention 
based on a novel method of flea and rodent control to 
ensure its efficacy in controlling plague.
These efforts represent the first steps in a long-
term collaboration that will greatly contribute to the 
understanding of plague and the development of 
policies and interventions to reduce its impact in Uganda. 
Additionally, research in Uganda provides an opportunity 
to increase CDC’s global emergency preparedness 
capabilities.  
Thailand Commits to Seasonal 
Flu Shots for Seniors
Asian cultures are generally known for commitment 
to their older adult population. An example of this 
commitment is Thailand’s bold step in February 2008 
5
to fund flu shots for seniors with chronic disease. This 
evidence-based policy decision is notable because it 
required Thailand –a middle income nation—to make a 
large government investment. The government moved 
forward because of the significant health impact this 
decision will have. More than five million people living 
in Thailand are over the age 
of 65 and many have serious 
conditions such as bronchitis, 
emphysema, asthma, heart 
disease, renal disease, diabetes, 
and hypertension. Without 
seasonal flu shots, they 
would be at risk for severe 
complications due to influenza 
infection.  
The government’s 
decision was influenced by 
high-quality data collected 
through collaboration with 
the Centers for Disease 
Control and Prevention (CDC) 
and the Thailand Ministry 
of Public Health (MOPH).  
“What’s great about this 
recent announcement is the 
opportunity to see our scientific work translated into 
public health policy,” says Mark Simmerman, Ph.D., chief of 
CDC’s Influenza Section in Thailand. In collaboration with 
Thai health officials, the CDC team has conducted active 
surveillance since 2003 and has presented data on the 
incidence, cost, risk factors, and seasonality of influenza 
since 2003.  
Thailand is no stranger to initiating policy decisions 
based on scientific evidence to protect the public’s health.  
The country organized a major vaccine campaign against 
Japanese encephalitis in 1998 and has given influenza 
vaccine to some health care workers and government 
veterinary workers for several years.  
“We have to look for the groups that will benefit 
most,” says Dr. Piyanit Tharmapornpilas, who manages 
the Expanded Program on Immunization for the MOPH.  
Research from other countries provides guidance about 
which groups those might be, but clear information 
specific to Thailand is available 
only from the population-
based studies conducted by 
the MOPH-CDC collaboration, 
according to Dr. Piyanit.  
The studies used to 
support the policy decision 
demonstrated that the disease 
and cost burden of influenza 
in Thailand were substantially 
greater than had previously 
been believed.  They identified 
young and advanced age, 
and underlying chronic 
disease—especially those with 
cardiopulmonary disease and 
previous hospitalization within 
the last year—as risk factors 
for severe complications from 
influenza infection.
In 2008 alone, the number of government-provided flu 
shots will nearly double to around 600,000. Those shots 
are expected to cover about 50% of the Thais who are 65 
or older and have chronic disease. According to Thai MOPH 
plans, a new government plant to manufacture flu shots 
locally will be operational by 2011, and will eventually 
have the capacity to produce more than 10 million doses 
annually.  This is one of several steps that Thailand is taking 
to prepare for an influenza pandemic, and represents how 
Thailand, with assistance from CDC, has been able to turn 
surveillance data into sound public health policy with the 
promise of prolonging the lives of its seniors.  
The US CDC is assisting the Chinese 
Center for Disease Control and 
Prevention (China CDC), with 
support from private technology 
companies and the CDC Foundation, 
to strengthen China CDC’s health 
informatics capacities.  This timely 
partnership will be used for rapid 
public health assessments in 
Sichuan province’s post-earthquake 
environment. CDC experts in 
informatics, mobile computing, 
and natural disaster epidemiologic 
surveillance were deployed to 
Beijing to help design and develop 
a platform of data collection and 
management which is based on PDA 
and mobile technology systems and 
tools. As efforts in the affected areas 
shift from emergency response to 
recovery, the health and well-being of 
the approximately 5 million displaced 
persons and the re-building of health 
systems are chief concerns. “With 
the new system and equipment, 
China CDC will collect public health 
data in earthquake-affected areas 
where communications capacity 
has been destroyed and send it to 
headquarters for analysis. This allows 
China CDC to rapidly get the right 
resources to the right places to save 
lives by preventing or reducing 
disease and injury,” said Dr. Leslie A. 
Lenert, Director of CDC’s National 
Center for Public Health Informatics.  
US CDC informatics experts will 
continue to provide guidance to 
China CDC in coming weeks on how 
to use the donated technology in a 
systematic and sustainable way to 
best manage disease control and 
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Thai government officials look on as Minister of Commerce Mingkwan Saengsuwan 
helps kick off a campaign to promote flu shots among senior citizens.  
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prevention while the Sichuan public 
health system is rebuilt.  
 
The press release is available on the 
US Embassy Beijing website at: http://
beijing.usembassy-china.org.
cn/070208p.html
Update to 2008 first qaurter e-brief: 
CDC is continuing to monitor yellow 
fever outbreak in South America in 
three countries: Brazil, Argentina, and 
Paraguay. As of June 26, 78 cases and 
34 deaths have been confirmed.   
Since February 2008, CDC has been 
involved in the detection, verification, 
and investigation of a monkeypox 
outbreak in the Democratic 
Republic of Congo. CDC supported 
deployment of a 9-person team to the 
affected area.  The team engaged in 
epidemiologic investigations, health 
care worker education, ecologic 
survey activities and patient care. 
The CDC team helped train health 
care workers from across the affected 
area in monkeypox recognition, 
specimen collection, reporting, 
patient care and proper infection 
control practices.  Surveillance data 
were reviewed to determine the 
extent and duration of the suspected 
epidemic, and information about 
interactions between people and 
wildlife was gathered to learn more 
about how the virus is transmitted 
from animals to people.  As a result of 
the assistance, CDC and the Ministry 
of Health have strengthened their  
collaborations on orthopoxvirus 
research and disease detection and 
control.
The presidential elections in Kenya 
conducted on December 
27, 2007, were contested, 
and shortly after violence 
erupted in multiple locations 
throughout the country. 
More than 1,000 people 
were killed and 350,000 
people displaced. There were 
disruptions in availability of 
food and fuel, and there was 
displacement of some CDC 
staff, including an authorized 
departure from Kisumu to 
Nairoibi for USG employees. 
On February 28, a widely 
accepted power-sharing 
agreement between 
the Kenya Government and the 
opposition was signed, and threats of 
political demonstrations and violence 
have dropped dramatically. As a 
result, the US Embassy cancelled the 
authorized departure for Kisumu and 
surrounding areas, and CDC staff and 
their families have been allowed to 
return.  Although the power-sharing 
agreement has eased tension and 
reduced unrest, the conflict affected 
CDC-Kenya’s programmatic, research, 
and administrative activities.
Throughout the weeks of unrest, 
CDC-Kenya staff proved themselves 
to be resourceful, caring, competent 
and hard working. Through long 
hours, strategic planning, and regular 
communications, staff at CDC-Kenya, 
including employees of the KEMRI-
CDC collaboration in Kisumu, ensured 
the continuity and quality of public 
health activities, including these: 
     * HIV programs that provide 
prevention services, care, and 
antiretroviral treatment to tens of 
thousands of people with HIV;  
     * more than 40 public health 
studies, and  
     *  intensive community-based 
disease surveillance.  
Although the violence has subsided, 
the impacts on public health in Kenya 
may extend for years to come.  These 
may include increases in mental illness, 
substance abuse, and unemployment  
and disruptions in food supply, 
immunizations, medications, and 
health services. Besides resuming their 
normal public health operations, the 
CDC-KEMRI collaboration is evaluating 
the public health impact of the 
post-election violence to identify and 
respond to any lasting public health 
problems in Kenya.  These activities 
are described in a Letter to the editor 
to the American Journal of Tropical 
Medicine and Hygiene (May 2008).  
 
The WHO cites delays in tuberculosis 
diagnosis as the leading risk factor for 
tuberculosis (TB) transmission within 
health care facilities.  A recent study 
conducted by CDC-Thailand and the 
Thailand Ministry of Public Health 
found that almost 75% of patients 
hospitalized with clinical pneumonia 
were not adequately evaluated for 
TB.  High rates of TB in Thailand 
and frequent diagnostic delays 
coupled with these data suggest that 
interventions should be implemented 
to ensure that hospital clinicians in 
Thailand consider performing a TB 
laboratory evaluation for all adults 
hospitalized with clinical pneumonia.  
Early screening interventions have 
the potential to prevent infection and 
devastating hospital outbreaks of TB, 
including drug-resistant TB. The full 
study can be found in the July issue 




COGH is pleased to bring you this 
podcast of the recent visit to CDC by 
United Nations Secretary General Ban 
Ki-Moon: http://www2a.cdc.gov/
podcasts/player.asp?f=9305. The 
link also includes a transcript.  
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Fredrick Miruka a Clinical Officer at KEMRI-CDC speaks to a patient during the 
medical camp.
